DeepKinase

DeepKinase (嘉华药锐) is a Chinese biotech startup in FreeS Fund's healthcare portfolio, working on applying data-driven methods to improve drug R&D efficiency — FreeS grouped it with its AI-drug-discovery bets alongside XtalPi, METiS and others . Co-founder Yun Xiao, a Peking University life-science graduate, previously worked at medical companies including Abbott, Wantai, Fresenius and STAGO . FreeS backed it at the angel round, and as of mid-2023 the company had raised over 100M RMB in a Series A co-led by Lapam Capital and BioTrack Capital, plus tens of millions in an A+ round solely funded by JunShan Capital, with FreeS continuing to add . FreeS also listed it among its healthcare companies that closed at least one round in the difficult 2022 market . elsewhere's corpus doesn't go beyond this funding-and-team outline — details of its specific technology or pipeline aren't covered.